GENE ONLINE|News &
Opinion
Blog

2020-12-13| M&A

Hoping to Boost Revenue Growth, Gilead Acquires MYR in a $1.4 B Deal

by Sangeeta Chakraborty
Share To

Gilead sciences expects to expand its hepatitis pipeline by acquiring MYR GmbH in an all-cash deal worth $1.4 B (1.15 B euros), payable upon closing of the transaction. MYR, German biotech based in Bad Homburg, is developing hepcludex (bulevirtide)—a first-in-class medicine—to treat chronic hepatitis delta virus (HDV) infection. Under the terms of the sale and purchase agreement, Gilead will pay an additional milestone payment of up to $362 M, reported as 300 M euros, upon FDA approval.

In July of this year, MYR received conditional approval to market hepcludex from the European Medicines Agency (EMA), making it the first and only approved medicine for HDV. MYR is currently selling the drug in France, Germany, and Austria and plans to launch in more countries next year. The company intends to seek accelerated approval from the FDA in the second half of 2021. The FDA has already granted both Orphan Drug and Breakthrough Therapy designations for use in chronic HDV cases.

 

Hepatitis D

Hep D is a severe form of viral hepatitis with extremely high death rates in cirrhotic patients; however, the infection can be transmitted only to patients who are already infected with hepatitis B. Around 12 million people worldwide are reported to have the disease, with about 230,000 in the US and Europe, while the condition largely remains underdiagnosed.

“HDV is a devastating disease with a high unmet medical need. With Hepcludex, we have the opportunity to address that need with a first-in-class therapy,” said Daniel O’Day, Chairman, and Chief Executive Officer, Gilead Sciences. “We look forward to working with the team at MYR to realize the full potential of Hepcludex for patients with HDV worldwide. This will build on the work that Gilead has been doing for almost two decades to innovate and improve therapies for viral hepatitis.”

“We are proud of our achievement in bringing Hepcludex from preclinical stage to patients in need within such a short timeframe,” said Dmitry Popov, Chief Executive Officer, MYR GmbH. “We are excited to join Gilead, whose experience in the hepatitis field and global infrastructure will realize the full potential of Hepcludex and provide access to as many patients as possible around the world with this debilitating disease.”

 

Hepcludex

Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP, an essential HBV and HDV receptor on liver cells. HDV co-infection is much worse than HBV alone in causing severe liver disease and cirrhosis and increases the risk of liver cancer and death. The drug has been tested in more than 500 patients in completed and ongoing clinical studies. The benefit of hepcludex includes an effective reduction of viral RNA and improvement of liver inflammation.

By Sangeeta Chakraborty, Ph.D.

Related Article: AstraZeneca to Acquire Alexion for US$ 39 Billion to Grow Immunology Pipeline

References
  1. https://uk.reuters.com/article/myr-m-a-gilead/gilead-to-acquire-german-biotech-firm-myr-for-about-115-billion-euros-idUKKBN28K1QC

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
LATEST
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
Advancing Healthcare Accessibility and Sustainable Development
2024-06-11
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
2024-06-11
EVENT
Scroll to Top